Estonia Pharmaceuticals and Healthcare Report Q2 2016

85 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: We expect growth in Estonia’s healthcare expenditure to decelerate over the long term given the
country’s fiscally conservative nature, the limited capacity of the national health insurer to accommodate
further healthcare spending growth and BMI’s outlook for the country’s economy over the long term.
Drugmakers can expect to see constrained revenue growth in the country as pricing pressures and
restrictive drug reimbursement are employed by the Estonian health insurance fund to restrict healthcare
expenditure.
Headline Expenditure Projections
? Pharmaceuticals: Sales will rise from EUR310mn (USD341mn) in 2015 to EUR328mn (USD351mn) in
2016, up 6.0% in local currency terms and down 3.2% in US dollar terms. Forecast stayed flat from last
quarter.
? Healthcare: Spending will rise from EUR1.22bn (USD1.34bn) in 2015 to EUR1.29bn (USD1.38bn) in
2016, up 5.8% in local currency terms and down 2.9% in US dollar terms. Forecast stayed flat from last
quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Estonia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Leading Anatomical Therapeutic Chemical (ATC) Groups By Pharmaceutical Sales, 2004-2010 (%) 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 22
Generic Drugs Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2014-2020) 30
Pharmaceuticals Risk/Reward Index 31
Central And Eastern Europe Risk/Reward Index 31
Estonia Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 42
Pricing Regime 43
Reimbursement Regime 44
Table: Key Health Insurance Indicators, 2007-2011 44
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000) 46
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Estonia 2010-2015) 51
Table: Healthcare Personnel (Estonia 2010-2015) 51
Table: Healthcare Activity (Estonia 2010-2015) 52
Table: HIF Healthcare Expenditure, 2006-2011 (EURmn) 53
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn) 54
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn) 55
Research And Development 56
Table: Members Of EBio, 2011 57
Clinical Trials 59
Table: Leading Causes Of Death, 2005-2010 61
Competitive Landscape 63
Research-Based Industry 63
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia 64
Table: Table: Multinational Market Activity 64
Generic Drugmakers 65
Pharmaceutical Distribution 66
Pharmaceutical Retail Sector 67
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 68
Company Profile 70
Grindeks (incorporating Tallinn Pharmaceutical Plant) 70
Demographic Forecast 74
Table: Population Headline Indicators (Estonia 1990-2025) 75
Table: Key Population Ratios (Estonia 1990-2025) 75
Table: Urban/Rural Population & Life Expectancy (Estonia 1990-2025) 76
Table: Population By Age Group (Estonia 1990-2025) 76
Table: Population By Age Group % (Estonia 1990-2025) 77
Glossary 79
Methodology 81
Pharmaceutical Expenditure Forecast Model 81
Healthcare Expenditure Forecast Model 81
Notes On Methodology 82
Risk/Reward Index Methodology 83
Index Overview 84
Table: Pharmaceutical Risk/Reward Index Indicators 84
Indicator Weightings 85

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Estonia 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Estonia 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Estonia 2012-2020)
Table: Leading Anatomical Therapeutic Chemical (ATC) Groups By Pharmaceutical Sales, 2004-2010 (%)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Estonia 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Estonia 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Estonia 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Estonia 2014-2020)
Table: Key Health Insurance Indicators, 2007-2011
Table: Expenditure By Reimbursed Prescription Medicinal Products, 2005-2010 (EEK '000)
Table: Healthcare Resources (Estonia 2010-2015)
Table: Healthcare Personnel (Estonia 2010-2015)
Table: Healthcare Activity (Estonia 2010-2015)
Table: HIF Healthcare Expenditure, 2006-2011 (EURmn)
Table: Reimbursement Spending By Key Therapeutic Area, 2010-2011 (EURmn)
Table: Medicinal Products Reimbursed For Insured Patients, 2009-2011 (EURmn)
Table: Members Of EBio, 2011
Table: Leading Causes Of Death, 2005-2010
Table: Members Of The Association Of International Pharmaceutical Manufacturers In Estonia
Table: Table: Multinational Market Activity
Table: Pharmacies And Pharmacy Market Ratios, 2004-2009
Table: Population Headline Indicators (Estonia 1990-2025)
Table: Key Population Ratios (Estonia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Estonia 1990-2025)
Table: Population By Age Group (Estonia 1990-2025)
Table: Population By Age Group % (Estonia 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Estonia Pharmaceuticals and Healthcare Report Q4 2015BMI View: We expect growth in Estonia's healthcare expenditure to decelerate over the long term given the country's fiscally conservative nature, the limited capacity of the national health insurer to accommodate further healthcare spending growth and BMI's outlook for the country's economy over the long term. Drugmakers can expect to see constrained revenue growth in the country as pricing pressures and restrictive drug reimbursement will be employed by the Estonian health insurance […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Croatia Pharmaceuticals and Healthcare Report Q2 2015BMI View: We expect the newfound independence of the national health insurer (HZZO) to have negative consequences for the pharmaceutical sector, as it will use its purchasing power to extract price cuts from drugmakers. With Croatia's economy set to stagnate, containing costs will be a priority for the health insurer. We therefore expect growth to remain depressed over the short term. Headline Expenditure Projections ? Pharmaceuticals: HRK6.64bn (USD1.09bn) in 2013 to HRK6.37bn […]
  • Estonia Pharmaceuticals and Healthcare Report Q1 2016BMI View: Estonian pharmaceutical sales posted larger than expected growth in 2014, but we expect pharmaceutical sales growth to have decelerated in 2015 as the impact of the Russian slowdown moderates economic activity. With Estonia seeing external tailwinds from the eurozone and Scandinavian countries, we expect pharmaceutical sales to stay largely flat in 2016 and beyond. Western-Russian relations will continue to present downside risk to our forecasts. Headline Expenditure […]
  • Poland Pharmaceuticals and Healthcare Report Q1 2015BMI View: Released retail pharmacy and national health insurance reimbursement data supports our earlier assertion of a rebound in Q214 and reinforces our full-year forecast for pharmaceutical sales in Poland. We see unemployment trending downwards and rising household consumption boosting overall GDP growth and feeding into an uptick in healthcare expenditure and pharmaceutical sales over the next five years. Over-the-counter medicines and generics will continue to be the primary […]